There is growing evidence on tenofovir disoproxil fumarate (TDF)-associated...
There is growing evidence on tenofovir disoproxil fumarate (TDF)-associated nephrotoxicity, however, its use in the management of HIV-1 infection is...
15 Feb, 2019
A number of factors including chronic inflammation, immune activation, traditional risk factors and exposure to antiretroviral drugs are reported to...
12 Feb, 2019
Hypertension (HTN) is considered an important cause of morbidity and mortality among people living with HIV (PLHIV) in resource-limited settings. A...
11 Feb, 2019
The effects of metabolic syndrome (MS) in HIV-1-infected patients on cardiovascular risk is poorly explored in sub-Saharan Africa. Recently, a cross...
This trial compares the safety and efficacy of TAF vs TDF co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of...
This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.
Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...
The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....